Back

Kyverna targets Q4 2026 BLA filing for Stiff Person syndrome therapy

Verifying
  • Kyverna Therapeutics is advancing a cell therapy for Stiff Person syndrome.
  • Q4 2026 is Kyverna Therapeutics’ target window for submitting the BLA.
  • Stiff Person syndrome is a rare autoimmune disease with no current approved treatments.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.